|
| 34990422 | Anal Adenocarcinoma: A Rare Entity in Need of Multidisciplinary Management. | Dis Colon Rectum | 2022 |
| 35473998 | Pancreatic cancer growth promoted by bone marrow mesenchymal stromal cell-derived IL-6 is reversed predominantly by IL-6 blockade. | Cytotherapy | 2022 |
| 36407947 | Combined Targeting of the Glutathione and Thioredoxin Antioxidant Systems in Pancreatic Cancer. | ACS Pharmacol Transl Sci | 2022 |
| 36636049 | A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. | J Gastrointest Oncol | 2022 |
| 35869145 | Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. | Br J Cancer | 2022 |
| 35978831 | Digital quantitative tissue image analysis of hypoxia in resected pancreatic ductal adenocarcinomas. | Front Oncol | 2022 |
| 35067501 | Impact of Definitive Chemoradiation on Quality-of-Life Changes for Patients With Anal Cancer: Long-term Results of a Prospective Study. | Dis Colon Rectum | 2022 |
| 32897623 | An Iodinated DAPI-Based Reagent for Mass Cytometry. | Chembiochem | 2021 |
| 33962950 | NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4. | Sci Adv | 2021 |
| 33169241 | Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, <sup>111</sup>In or β-particle emitting, <sup>177</sup>Lu. | EJNMMI Radiopharm Chem | 2020 |
| 32005829 | Quantifying Reoxygenation in Pancreatic Cancer During Stereotactic Body Radiotherapy. | Sci Rep | 2020 |
| 32062317 | Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [<sup>64</sup>Cu]Cu-NOTA-panitumumab F(ab')<sub>2</sub> alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib. | Nucl Med Biol | 2020 |
| 30686769 | Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. | Cancer Cell | 2019 |
| 30117091 | Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients. | J Gastrointest Cancer | 2019 |
| 31242384 | MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with <sup>99m</sup>Tc(I) Tricarbonyl Complex. | Mol Pharm | 2019 |
| 31520102 | Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. | Cancer Chemother Pharmacol | 2019 |
| 31633216 | Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). | Eur J Immunol | 2019 |
| 30654137 | Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability. | Biol Blood Marrow Transplant | 2019 |
| 30629588 | Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. | PLoS Comput Biol | 2019 |
| 30589553 | Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to <sup>177</sup>Lu. | Mol Pharm | 2019 |
| 29288237 | Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. | Clin Cancer Res | 2018 |
| 29755663 | The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy. | Oncotarget | 2018 |
| 29441441 | Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. | J Genet Couns | 2018 |
| 29128266 | Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. | Clin Colorectal Cancer | 2018 |
| 29314858 | Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to <sup>111</sup>In and <sup>177</sup>Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer. | Mol Pharm | 2018 |
| 27875522 | Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts. | Br J Cancer | 2017 |
| 33465927 | EGFR-Targeted Metal Chelating Polymers (MCPs) Harboring Multiple Pendant PEG<sub>2K</sub> Chains for MicroPET/CT Imaging of Patient-Derived Pancreatic Cancer Xenografts. | ACS Biomater Sci Eng | 2017 |
| 28480074 | Long term responders to palliative chemotherapy for advanced biliary tract cancer. | J Gastrointest Oncol | 2017 |
| 28160444 | Imaging Mass Cytometry. | Cytometry A | 2017 |
| 28967989 | Staining of Frozen and Formalin-Fixed, Paraffin-Embedded Tissues with Metal-Labeled Antibodies for Imaging Mass Cytometry Analysis. | Curr Protoc Cytom | 2017 |
| 29273939 | Impact of tissue transport on PET hypoxia quantification in pancreatic tumours. | EJNMMI Res | 2017 |
| 29023707 | Guidelines for the use of flow cytometry and cell sorting in immunological studies. | Eur J Immunol | 2017 |
| 27768182 | Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. | JAMA Oncol | 2017 |
| 27902970 | Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts. | Oncotarget | 2017 |
| 27901496 | Cancer initiating-cells are enriched in the CA9 positive fraction of primary cervix cancer xenografts. | Oncotarget | 2017 |
| 26732437 | A phase I study of elesclomol sodium in patients with acute myeloid leukemia. | Leuk Lymphoma | 2016 |
| 27812005 | Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues. | Sci Rep | 2016 |
| 28033382 | Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. | PLoS One | 2016 |
| 27779123 | Quantifying hypoxia in human cancers using static PET imaging. | Phys Med Biol | 2016 |
| 27745984 | Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. | Int J Radiat Oncol Biol Phys | 2016 |
| 27709819 | Isotopologous Organotellurium Probes Reveal Dynamic Hypoxia In Vivo with Cellular Resolution. | Angew Chem Int Ed Engl | 2016 |
| 27422303 | A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer. | Cancer Chemother Pharmacol | 2016 |
| 27552306 | Porphysome nanoparticles for enhanced photothermal therapy in a patient-derived orthotopic pancreas xenograft cancer model: a pilot study. | J Biomed Opt | 2016 |
| 27467054 | FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. | Br J Cancer | 2016 |
| 27406088 | A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. | Invest New Drugs | 2016 |
| 27248663 | Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302. | Oncotarget | 2016 |
| 27542226 | Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma. | Oncotarget | 2016 |
| 26890070 | Cytokinetic effects of Wee1 disruption in pancreatic cancer. | Cell Cycle | 2016 |
| 26686201 | A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI⿯9041). | Invest New Drugs | 2016 |
| 26769863 | Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on 18F-Fluoroazomyin Arabinoside Uptake. | J Nucl Med | 2016 |